Riskpilot← Back to searchSign inGet full accessInDex Diagnostics AB
ABIn liquidationOrg 5566022751StockholmResearch and experimental development on biotechnology · NACE 7211Est. 20000 employees
Revenue 2023
SEK 0
EBITDA margin
—
-67% vs 2022
Equity ratio
30.9%
Financial strength
Net profit 2023
SEK -5K
-67% vs 2022
| Revenue | SEK 0 | — |
| EBITDA | SEK -5K | -67% |
| Net profit | SEK -5K | -67% |
| Total assets | SEK 1,1M | +0% |
| Equity | SEK 349K | -1% |
| Employees | 0 | — |
Legal name
InDex Diagnostics AB
Org number
5566022751
Legal form
Aktiebolag
NACE code
7211 · Research and experimental development on biotechnology
Founded
12 december 2000
Share capital
SEK 324 000
Employees
0
VAT registered
No
Audit selected
No
Last report
2023-12-31
Financial year
January – December
Signatory rights
Firman tecknas ensam av likvidatorn
Company purpose
Bolaget skall bedriva forskning, teknikutveckling och kommers- ialiering av vetenskapliga upptäckter inom det biomedicinska området samt därmed förenlig verksamhet.
Address
Stockholm
Risika for professionals
Risika provides regulated workflow tools for finance, procurement and compliance teams that need monitoring, alerts and an API.
| Item | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|---|---|---|---|
| Revenue | — | — | — | 128 | 88 | 35 | 7 | 0 | 0 |
| Staff expenses | — | — | — | — | — | — | — | — | — |
| EBITDA | 119 | 21 | −355 | −190 | −141 | −166 | −1 | −3 | −5 |
| Depreciation & amort. | −29 | −6 | −0 | −0 | −0 | −0 | −0 | −0 | −0 |
| EBIT | 90 | 15 | −355 | −190 | −141 | −166 | −1 | −3 | −5 |
| Net financials | — | — | — | — | — | — | — | — | — |
| Profit before tax | 90 | 15 | −355 | −190 | −141 | −166 | −1 | −3 | −5 |
| Tax | −0 | −0 | −0 | −0 | −0 | −0 | −0 | −0 | −0 |
| Net profit | 90 | 15 | −355 | −190 | −141 | −166 | −1 | −3 | −5 |
| Item | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|---|---|---|---|
| Total assets | 747 | 849 | 581 | 578 | 936 | 1 137 | 1 136 | 1 133 | 1 128 |
| Equity | 745 | 760 | 405 | 215 | 373 | 357 | 357 | 354 | 349 |
| Long-term debt | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Short-term debt | 2 | 89 | 176 | 363 | 563 | 780 | 779 | 779 | 779 |
| Total debt | 2 | 89 | 176 | 363 | 563 | 780 | 779 | 779 | 779 |
EBITDA margin
-500000.0%
This company
15.8%
Market median
-3164657% vs market
20152023
Equity ratio
30.9%
This company
38.2%
Market median
+19% vs market
20152023
Return on equity
-1.4%
This company
18.4%
Market median
-108% vs market
20152023
Net profit margin
-500000.0%
This company
8.1%
Market median
-6172940% vs market
20152023
Asset turnover
0.00×
This company
1.12×
Market median
-100% vs market
20152023
Debt / equity
2.23×
This company
0.62×
Market median
-260% vs market
20152023
- Annual report 2023Filed via Bolagsverket / SCB · Period 2023-01-01 – 2023-12-31
- Annual report 2022Filed via Bolagsverket / SCB · Period 2022-01-01 – 2022-12-31
- Annual report 2021Filed via Bolagsverket / SCB · Period 2021-01-01 – 2021-12-31
- Annual report 2020Filed via Bolagsverket / SCB · Period 2020-01-01 – 2020-12-31
- Annual report 2019Filed via Bolagsverket / SCB · Period 2019-01-01 – 2019-12-31
- Annual report 2018Filed via Bolagsverket / SCB · Period 2018-01-01 – 2018-12-31
- Annual report 2017Filed via Bolagsverket / SCB · Period 2017-01-01 – 2017-12-31
- Annual report 2016Filed via Bolagsverket / SCB · Period 2016-01-01 – 2016-12-31
- Annual report 2015Filed via Bolagsverket / SCB · Period 2015-01-01 – 2015-12-31
| Name | Role | Member since | Age | Other directorships |
|---|---|---|---|---|
JS Chief Executive Officer | Chief Executive Officer | 2020 | — | — |
BM Chief Auditor | Chief Auditor | 2020 | — | — |
KS Liquidator | Liquidator | 2024 | — | — |
CJ Deputy Chief Executive Officer | Deputy Chief Executive Officer | 2022 | — | — |
| Name | Role | Member since | Age | Other directorships |
|---|---|---|---|---|
| Board of Directors | 2020 | — | — | |
| Chairman | 2022 | — | — | |
| Chairman | 2020 | — | — | |
| Board of Directors | 2022 | — | — |
| Shareholder | Type | Ownership | Votes | Since |
|---|---|---|---|---|
InDex Pharmaceuticals AB | Company | 100.0% | 100.0% | 0001 |
Beneficial ownership (UBO) data access is restricted in Denmark as of September 2025 per the EU 6th AML Directive. Learn more.
Flerie AB
InDex Diagnostics AB Board members of InDex Diagnostics AB also hold positions in 0 other companies.
| Person | Role here | Other companies |
|---|---|---|
| Jenny Sundqvist | Chief Executive Officer | 0 companies |
| Bo Magnus Lagerberg | Chief Auditor | 0 companies |
| Karl Sten Mathias Winge | Liquidator | 0 companies |
| Carl Johan Giléus | Deputy Chief Executive Officer | 0 companies |
| Stig Lennart Hansson | Board of Directors | 0 companies |
| Peter Hakim Zerhouni | Chairman | 0 companies |
| Wenche Nelly A Rolfsen Sandsborg | Chairman | 0 companies |
| Pernilla Helena Sandwall | Board of Directors | 0 companies |